Literature DB >> 32890578

Delineation of metabolic responses of Npc1-/-nih mice lacking the cholesterol-esterifying enzyme SOAT2 to acute treatment with 2-hydroxypropyl-β-cyclodextrin.

Charina M Ramirez1, Anna M Taylor2, Adam M Lopez3, Joyce J Repa4, Stephen D Turley5.   

Abstract

Lipids present in lipoproteins cleared from the circulation are processed sequentially by three major proteins within the late endosomal/lysosomal (E/L) compartment of all cells: lysosomal acid lipase (LAL), Niemann-Pick (NPC) C2 and NPC1. When all three of these proteins are functioning normally, unesterified cholesterol (UC) exits the E/L compartment and is used in plasma membrane maintenance and various pathways in the endoplasmic reticulum including esterification by sterol O-acyltransferase 2 (SOAT2) or SOAT1 depending partly on cell type. Mutations in either NPC2 or NPC1 result in continual entrapment of UC and glycosphingolipids leading to neurodegeneration, pulmonary dysfunction, splenomegaly and liver damage. To date, the most effective agent for promoting release of entrapped UC in nearly all organs of NPC1-deficient mice and cats is 2-hydroxypropyl-β-cyclodextrin (2HPβCD). The cytotoxic nature of the liberated UC triggers various defenses including suppression of sterol synthesis and increased esterification. The present studies, using the Npc1-/-nih mouse model, measured the comparative quantitative importance of these two responses in the liver versus the spleen of Npc1-/-: Soat2+/+ and Npc1-/-: Soat2-/- mice in the 24 h following a single acute treatment with 2HPβCD. In the liver but not the spleen of both types of mice suppression of synthesis alone or in combination with increased esterification provided the major defense against the rise in unsequestered cellular UC content. These findings have implications for systemic 2HPβCD treatment in NPC1 patients in view of the purportedly low levels of SOAT2 activity in human liver.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholesterol synthesis and esterification; Liver; Lysosomal storage disease; Spleen; Unesterified cholesterol sequestration

Year:  2020        PMID: 32890578      PMCID: PMC7680374          DOI: 10.1016/j.steroids.2020.108725

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  73 in total

1.  Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream.

Authors:  Anna M Taylor; Bing Liu; Yelenis Mari; Benny Liu; Joyce J Repa
Journal:  J Lipid Res       Date:  2012-08-14       Impact factor: 5.922

Review 2.  Cholesterol ester metabolism.

Authors:  D S Goodman
Journal:  Physiol Rev       Date:  1965-10       Impact factor: 37.312

3.  [Qualitative and quantitative estimation of free and esterified sterols in whole rat and in 23 of its tissues and organs].

Authors:  F d' Hollander; F Chevallier
Journal:  Biochim Biophys Acta       Date:  1969-01-21

4.  Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease.

Authors:  J L Goldstein; S E Dana; J R Faust; A L Beaudet; M S Brown
Journal:  J Biol Chem       Date:  1975-11-10       Impact factor: 5.157

5.  Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.

Authors:  F Camargo; R P Erickson; W S Garver; G S Hossain; P N Carbone; R A Heidenreich; J Blanchard
Journal:  Life Sci       Date:  2001-11-30       Impact factor: 5.037

6.  Effect of cholesterol feeding and fasting on sterol synthesis in seventeen tissues of the rat.

Authors:  J M Dietschy; M D Siperstein
Journal:  J Lipid Res       Date:  1967-03       Impact factor: 5.922

7.  Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol.

Authors:  G J Warner; G Stoudt; M Bamberger; W J Johnson; G H Rothblat
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

Review 8.  Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).

Authors:  Laura J Sharpe; Andrew J Brown
Journal:  J Biol Chem       Date:  2013-05-21       Impact factor: 5.157

Review 9.  Recommendations for the detection and diagnosis of Niemann-Pick disease type C: An update.

Authors:  Marc C Patterson; Peter Clayton; Paul Gissen; Mathieu Anheim; Peter Bauer; Olivier Bonnot; Andrea Dardis; Carlo Dionisi-Vici; Hans-Hermann Klünemann; Philippe Latour; Charles M Lourenço; Daniel S Ory; Alasdair Parker; Miguel Pocoví; Michael Strupp; Marie T Vanier; Mark Walterfang; Thorsten Marquardt
Journal:  Neurol Clin Pract       Date:  2017-12

Review 10.  Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.

Authors:  Caroline Coisne; Sébastien Tilloy; Eric Monflier; Daniel Wils; Laurence Fenart; Fabien Gosselet
Journal:  Molecules       Date:  2016-12-20       Impact factor: 4.411

View more
  2 in total

Review 1.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

2.  Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics.

Authors:  Jorge L Rodriguez-Gil; Laura L Baxter; Dawn E Watkins-Chow; Nicholas L Johnson; Cristin D Davidson; Steven R Carlson; Arturo A Incao; Kerri L Wallom; Nicole Y Farhat; Frances M Platt; Ryan K Dale; Forbes D Porter; William J Pavan
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 5.121

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.